Approved antibiotics and those under clinical development are insufficient to arrest AMR: Rex Clements, Centrient Pharmaceuticals
Flagging off World Antimicrobial Awareness Week from November 18-24, Rex Clements, CEO, Centrient Pharmaceuticals, in an email interaction with Viveka Roychowdhury suggests that since it does not make business sense for the pharma industry to continue investing in the R&D of new antibiotics, governments and innovative solutions like insurance can come in to steer and fund antibiotic discovery. On India’s National Action Plan for AMR, he says they can be further sharpened if stringent antibiotic residue limits are prescribed for the pharma industry and responsible manufacturing is rewarded while discouraging pharma emissions
